Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lauren Scarpetti"'
Autor:
Lauren Scarpetti, Chetan C Oturkar, Dejan Juric, Maria Shellock, Giuliana Malvarosa, Kathryn Post, Steven Isakoff, Nancy Wang, Brian Nahed, Kevin Oh, Gokul M Das, Aditya Bardia
Publikováno v:
The Oncologist. 28:358-363
The absence of effective therapeutic targets and aggressive nature of triple-negative breast cancer (TNBC) renders this disease subset difficult to treat. Although estrogen receptor beta (ERβ) is expressed in TNBC, studies on its functional role hav
Autor:
Laura M Spring, Lauren Scarpetti, Andrzej Niemierko, Steven J Isakoff, Beverly Moy, Seth A Wander, Elisabeth Smith, Elizabeth Abraham, Jennifer Shin, Jaymin M Patel, Amy Comander, Therese Mulvey, Aditya Bardia
Publikováno v:
Cancer Research. 82:P1-14
Background: CDK 4/6 inhibitors have demonstrated substantial efficacy in treating ER+/HER2- metastatic breast cancer. Therefore, there is great interest in exploring their ability to reduce recurrence risk in early breast cancer. However, conflicting
Autor:
Kristen M. Shannon, Whitfield B. Growdon, Lauren Scarpetti, Rachel C. Sisodia, Linda H Rodgers, Erica Blouch, Annekathryn Goodman, Eric L. Eisenhauer, Marcela G. del Carmen, Stephanie Alimena
Publikováno v:
International Journal of Gynecologic Cancer. 30:1397-1403
ObjectiveThe National Comprehensive Cancer Network recommends that all women diagnosed with epithelial ovarian cancer undergo genetic testing, as the diagnosis of pathogenic variants may inform cancer survival and impact treatment options. The object
Autor:
Karleen Habin, Dejan Juric, Elizabeth Tripp, Maureen Beeler, Beverly Moy, Rachel Hepp, Leif W. Ellisen, Lauren Scarpetti, Elene Viscosi, Aditya Bardia, Steven J. Isakoff, Seth A. Wander, Laura Spring, Neelima Vidula
Publikováno v:
Cancer Research. 80:OT2-08
Background: The cyclin-dependent 4/6 inhibitors (CDK4/6i), in combination with an anti-estrogen, have emerged as the standard of care for patients with HR+/HER2- MBC. While only limited insight exists into the molecular factors that drive progression
Publikováno v:
The FASEB Journal. 33
Autor:
Elene Viscosi, Steven J. Isakoff, Leif W. Ellisen, Rachel Hepp, Douglas S. Micalizzi, Laura Spring, Neelima Vidula, Dejan Juric, Jeffrey G. Supko, Aditya Bardia, Maureen Beeler, Karleen Habin, Donna M. Fitzgerald, Seth A. Wander, Lauren Scarpetti, Beverly Moy, Elizabeth Tripp
Publikováno v:
Journal of Clinical Oncology. 38:1066-1066
1066 Background: The cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), with an anti-estrogen, are the standard of care for HR+/HER2- MBC. Insights from patient biopsies and preclinical analysis suggest that AKT1 activation can provoke CDK4/6i resista